Related Experiment Video
Updated: Jun 13, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Treatment of HIV infection with the CCR5 antagonist maraviroc
Wiete Kromdijk1, Alwin D R Huitema, Jan Willem Mulder
1Slotervaart Hospital, Department of Pharmacy & Pharmacology, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. wiete.kromdijk@slz.nl
Importance Of The Field:
The emergence of resistance in treatment-experienced HIV patients often limits therapeutic success of the currently available antiretroviral drugs. New drug classes are thus required. Maraviroc is the first chemokine receptor 5 antagonist approved for use in treatment experienced HIV patients with a R5-tropic virus.
Areas Covered In This Review:
For this review, data from pharmacokinetic, Phase II and III clinical trials were reviewed.
What The Reader Will Gain:
The objectives of this review were to discuss the pharmacokinetics and clinical efficacy and safety of maraviroc in treatment-experienced and -naive HIV patients with R5-tropic virus. Additionally, tropism testing was discussed.
Take Home Message:
Maraviroc is effective in previously treated patients with R5-tropic virus only. Also, maraviroc will be an attractive option for HIV-1-infected treatment-naive patients with R5-tropic viruses only, once genotypic assays have been validated.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Cryptococcal Meningitis
Retroviruses
Subviral Agents
Inhibitors of Viral Protein Synthesis

